{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-012938","form_type":"8-K","ticker":"PULM","cik":"0001574235","company_name":"Pulmatrix, Inc.","filed_at":"2022-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:04:01.270078+00:00","generated_at":"2026-06-25T18:22:14.887008+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Pulmatrix Q1 net loss widens to $5.0M; cash $47.5M extends runway to Q2 2024","bullets":["Net loss of $5.0M ($1.51 per share) vs $4.1M loss in Q1 2021; revenue fell to $1.2M from $1.4M.","Ended Q1 with $47.5M cash; cash runway extended into Q2 2024, through Pulmazole Phase 2b data readout.","Pulmazole Phase 2b on track to start dosing Q1 2023; top-line data expected Q2 2024.","PUR3100 Phase 1 top-line data expected in Q4 2022 from Australian study.","Completed 1-for-20 reverse stock split and regained Nasdaq compliance in March 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-012938","json":"https://secwatch.observer/filing/0001493152-22-012938.json","markdown":"https://secwatch.observer/filing/0001493152-22-012938.md","text":"https://secwatch.observer/filing/0001493152-22-012938.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1574235/000149315222012938/0001493152-22-012938-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1574235/000149315222012938/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T18:22:14.887008+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}